Compass Therapeutics, Inc Investor Event Transcript, Nov 9, 2026
Compass Therapeutics, Inc. (CMPX)
Compass Therapeutics is pursuing FDA engagement after Tevesimig more than tripled the overall response rate and reported a 0.44 progression-free survival hazard ratio, but overall survival did not differ in intent-to-treat analysis. AI summary
Conference Transcript - CMPX 2026-11-09
Michael Schmidt, Analyst — Guggenheim
All right, so welcome to this next fireside chat with Compass Therapeutics. I'm pleased to welcome Tom Schitts, CEO. Tom, welcome. Thanks for joining us.
Thomas J. Schuetz, CEO
Thanks so much, Michael. Thanks for inviting us. Thanks for having us here.
Michael Schmidt, Analyst — Guggenheim
Great. So I'm Michael Schmidt, Senior Biotech Analyst with Guggenheim, in case you don't know me. So, Tom, this has been, I would say, arguably a difficult year for Compass. How would you describe the company's strategy and priorities today?
Thomas J. Schuetz, CEO
Sure. Of course, I'm not going to argue with you. It has been somewhat of a difficult year. You know, we're... Luckily, you know, we're extremely well-funded. We just announced our earnings this morning. You know, we're funded into 2028, you know, for all of our development programs. And I think, like all difficult times, right, really focus on the mission. And, you know, we're really focused on, you know, developing a set of new drugs. We've got four drugs in the clinic. We can talk about each of those individual drugs, and we're really focused on advancing these programs to so-called inflection points, which will be driven by the clinical data. So, you know, we're just really, really focused on... Not the difficulty, but the real opportunity, you know, with developing these drugs in these indications.
Michael Schmidt, Analyst — Guggenheim
So I do want to spend some time to discuss the companion OO2 data. So you obviously just came off the ESMO presentation, the first sort of full presentation at a medical conference. Maybe just stepping back. What have you learned about Tivesimig today and its opportunity to treat biliary tract cancers?
Thomas J. Schuetz, CEO
Sure. So in addition, of course, to the ESMO presentation, we simultaneously published all of the data in the Journal of Clinical Oncology on the 24th of October online. I think what have we learned about Tevesimig? I think let's start very, very simply, if you don't mind. The drug clearly works, right? There's just no question about it. So we more than tripled the overall response rate. Progression-free survival had a hazard ratio of 0.44, a hazard ratio on PFS that you don't see every day. So there's clearly activity with this drug, and I was very encouraged. We had a whole series of meetings with KOLs at ESMO, and every meeting we had, the KOLs started the meeting by saying, well, this drug clearly works. So we have an unequivocal efficacy signal, and I think that's a very, very good place to start the conversation.
Michael Schmidt, Analyst — Guggenheim
Obviously, the overall survival endpoint did not succeed for various reasons. We can get into this, but I just wanted to step back and maybe then bridge over to, you know, what this means for your regulatory submission and what the feedback has been to date from the FDA around that.
Thomas J. Schuetz, CEO
Sure. So let's talk about the endpoint first on the overall survival endpoint. So the study allowed crossover, of course. So more than half the patients who were randomized to the control arm crossed over to receive combination therapy with Tevesameg. And even though they crossed over, of course, in an intent-to-treat analysis, they are, quote-unquote, counted with the chemotherapy controller. So that's just the way the statistics work. So 85% of the patients in the study received combination therapy. So the study was effectively a randomized trial of Tevesimig versus Paclitaxel versus Tevesimig plus Paclitaxel. So the overall survival in the intent-to-treat analysis was not different. You know, fascinatingly, during the review of the draft of the JCO manuscript, one of the reviewers of that manuscript specifically asked for the two-stage estimation method, and we did that, and that showed a hazard ratio of 0.85 when you correct for crossover. So, you know, this question about the hazard ratio being above one, you know, hopefully we have put that question at least to rest. You know, the second half of your question, of course, is very complicated, right? How does this all connect on the regulatory front? So, you know, we submitted a meeting package in the summer. As I have said publicly, we were not afforded a meeting, and all of the responses were written responses only. So we never really had a discussion about the survival data. So as I sit here today, I don't really know what the answer to your question is. So what we have said publicly, and I'll say again today, we're working to re-engage with the FDA. We're right in the middle of that right now. We expect to have a meeting with the FDA, and hopefully, like many other companies, which you know these companies full well, over the past... Six to nine months, you know, have had rather dramatic reversals of their FDA trajectory based on, you know, a different approach. So, you know, we're trying that different approach. We're right in the middle of that. We'll see. Hopefully that will put us in a position where we can say something more definitive about the regulatory path.
Michael Schmidt, Analyst — Guggenheim
Right. And remind us, what was the initial feedback that you've received?
Thomas J. Schuetz, CEO
So we received written feedback, which was very, very short feedback. We attempted to go back and get that clarified, and the clarification was not super helpful to us. So we were in this very, very difficult position where we felt like we needed to make a disclosure. So, you know, FDA, quote, unquote, recommended, you know, that we do a study to demonstrate a survival advantage. So that's what we disclosed.
Michael Schmidt, Analyst — Guggenheim
So obviously, you know, going into this, you obviously knew that crossover is going to be an issue, right, in the study to show survival. That's why you had actually implemented some statistics to account for that. I guess, how persuasive is this alternative method that was included in the JZO paper compared to the RPSFT analysis?
Thomas J. Schuetz, CEO
So the RPSFT analysis could not be done because the statistical assumptions for that method were not met. So how persuasive will it be? I don't know the answer to that. I will say we only very recently disclosed that, and that entire analysis was not included in our original submission to the FDA in the summer.
Michael Schmidt, Analyst — Guggenheim
Okay, and outside the OS question, did the FDA have any other feedback on, you know, the magnitude of benefit, for example, on PFS, or any of the other activity measures that were assessed in the study? So, um...
Thomas J. Schuetz, CEO
So, you know, I think the short answer to that is, you know, if you're forced me to say yes or no, I suppose the answer is yes. You know, they had some additional comments on the data in the study, but again, we did not have any discussion whatsoever about those comments. So, and that's really what we're trying to accomplish here this quarter. What about safety? Any safety concerns? I don't think so. Nothing specific was brought up. I think we disclosed the entire safety data set in the JCO paper and the ESMO presentation. I think for the most part, it looks fairly similar to what you see with VEGF targeted agents. Maybe a little bit more hypertension, but a little less proteinuria. You know, maybe a little less clotting and bleeding. So, you know, it's, but it's, for the most part, you know, it's similar to other drugs in the class.
Michael Schmidt, Analyst — Guggenheim
Okay. The other thing that had been discussed also came up in the ESMO discussion, actually, was the control arm choice. Is that something the FDA okayed with the Paclitaxel as opposed to using a 4-Fox, which is recommended?
Thomas J. Schuetz, CEO
So the answer to that is definitely yes. So FDA specifically requested to have Paclitaxel as the control arm. I think, interestingly, I think the three-drug combination Folfax, I think, is more commonly used in the second-line setting in the EU than in the United States. And I think in the United States, there's... There's an incredible variety of second-line regimens that are used, Folfox, Fulfuri, even the SWAG-1815 that looked at Abraxane, some people use that. So, you know, there's a whole series on liposomal arena tecan. So none of these drugs or regimens, by the way, are labeled for this indication in the United States. So, you know, it's amazing today, you know, that we have a disease like biliary tract cancer in the U.S. that outside of actionable mutations has no labeled second-line therapy. I think it's one of the almost only diseases out there that doesn't have a labeled second-line therapy.
Michael Schmidt, Analyst — Guggenheim
So it seems like it all comes down to the OS, the way OS is being analyzed in the study at the end of the day.
Thomas J. Schuetz, CEO
I don't know. Honestly, that sounds crazy that I can't answer that question, but I honestly don't know what it comes down to because we haven't had a conversation with them.
Michael Schmidt, Analyst — Guggenheim
So, maybe then walk us through the next steps. So, the meeting, when is it coming up, and then what would you do subsequently to that?
Thomas J. Schuetz, CEO
Right. So, we have not disclosed anything about the details of the upcoming meeting. Ideally, we'd like to... You know, get alignment on the regulatory path forward, you know, with FDA, and I would, you know, I alluded, you know, to the fact, you know, that there were so many other companies, you know, that have, you know, sort of gone through this, you know, the recent, the recent disclosure by Biohaven, for example, right? You know, they, they recently disclosed that they have a PDUFA date now in, in the coming year, in which, you know, that was, you know, something completely new, obviously, you know, You and I have talked before about Replimune, right, and how that completely turned around from a negative CRL. So, yeah, just hopefully we'll be able to make some disclosure like those companies did where we reach agreement on next steps with FDA. That's the goal for this meeting.
Michael Schmidt, Analyst — Guggenheim
And if the answer, I think, I guess maybe walk us through what are possible outcome scenarios and how likely, No, let's not go there. Just walk us through the options post-meeting, in your opinion.
Thomas J. Schuetz, CEO
Sure. You know, I think one option would be, okay, your ORR and PFS data support accelerated approval. You know, let's talk about the design of a confirmatory study, and let's get that study up and running. Okay, that would be one, you know, potential outcome. And I think there would be, we're talking about a couple of different potential confirmatory studies, Probably the absolute simplest design would be another second-line study with Tevesimig plus Paclitaxel versus Folfox as a straight-up randomized overall survival study. And that's a study that we're talking to some cooperative groups about, which could be very financially efficient for us if we were able to do that. Of course, we could have a conversation about full approval. At the end of 2025, there was a 10,000 patient meta-analysis published in the Journal of Hepatology in biliary tract cancer, which showed that a PFS hazard ratio less than 0.61 is predictive of an overall survival benefit. And this is a little bit of a technicality, but once a surrogate endpoint is validated with a meta-analysis like that, it is no longer a surrogate endpoint. It's a full endpoint. I think the best example of this is serum cholesterol. You know, there's a long time when serum cholesterol was considered a surrogate. Not anymore, right? So, you know, so that is also a possibility. You know, I suppose, just to complete the thought and, you know, be fair to your question, you know, I suppose FDA could say none of this, you know, supports, supports approval. Okay. You know, then we would, you know, probably again, continue the conversations with the cooperative groups. We also have a number of investigator-sponsored studies ongoing, including a frontline biliary tract cancer study, adding Tevesimig to Gemsis and Dervolumab. We're starting to see some interesting data coming out of that right now, which could inform a frontline study, maybe with a partner. We could do that study, for example. So that would be a study that will get data from that. We also have a gastric cancer and colorectal cancer, as well as a glioblastoma study that are ongoing, and, you know, we're continuing to sort of see interesting data, you know, tumbling out of these studies.
Michael Schmidt, Analyst — Guggenheim
There's been some new data reported on ivanesimab. In BTC. How does that factor in, or does that factor into your thinking at all for next steps?
Thomas J. Schuetz, CEO
So that, the ivanesimab data were also presented at ESMO two weeks ago. So I listened. I was at that presentation. Yeah, I was super happy to see that result, right, because, you know, I think what the Ivanesimab data showed is that VEGF blockade in this disease is a valid therapeutic target, right? We already knew that checkpoint inhibition was meaningful in this disease with both MFINZI and Keytruda labeled in the frontline setting. So Ivanessimab provides PD-1 blockade via one end of the molecule and VEGF blockade via the other end, and that was superior to MFINZI. So, you know, I think what the Harmony GI study showed was that blocking the VEGF and the angiogenesis pathway is a valid. You know, therapeutic modality in this disease. So I was super happy about that. In terms of what that means for us in a frontline study, I don't know. I'm not sure. We've heard rumors about a cooperative group study in the United States. I don't know anything about that. I just heard rumors, so I don't know. And I think Ivinasimab has a PDUFA Day coming up, so obviously we'll follow that very, very closely.
Michael Schmidt, Analyst — Guggenheim
Sounds good. And so when will you, just to summarize this, when will you be able to update markets on these regulatory discussions and next steps?
Thomas J. Schuetz, CEO
Sure. You know, I think... We'd love to, I would love for that to be able to happen this calendar year. I don't know if we're going to be able to do that or not. That is forward-looking, as our lawyer friends say. I think sometime in the next several months, at minimum, we should be able to provide an update on the regulatory path forward in the United States.
Michael Schmidt, Analyst — Guggenheim
Okay, great. So looking forward to that. Maybe then a few minutes on the pipeline, the rest of the pipeline. Which of the programs are you most excited about right now?
Thomas J. Schuetz, CEO
You know, we have four drugs in development, so I'm excited about all our drugs, of course. You know, I think on Friday, only three days ago, we announced and Saturday we presented novel scientific data for our own PD-1-VEGF bispecific antibody, which is called 10726. Interestingly, we showed a couple of years ago that our PD-1, PD-L1 bispecific antibody, which I'll come to in a minute, was able to... Mediate PD-1 stripping off the surface of effector T cells. So our drug 8371 converts PD-1 positive T cells into PD-1 negative T cells. It's a very unique and novel mechanism of action. And because we took the component, the PD-1 blocking component, out of that drug and put it into the PD-1 VEGF bispecific, we wondered whether or not we could also mediate PD-1 stripping with that drug. And fascinatingly, we do mediate PD-1 stripping, but only in the presence of VEGFA. So, VEGFA is able to mediate the formation of multimers, probably, that then mediate PD-1 stripping. So, that drug also converts PD-1 positive T-cells into PD-1 negative T-cells, and we believe we have a very well-differentiated mechanism of action within what is now unequivocally A new class of drugs. So that's very exciting. We're in a dose escalation phase one study right now. We'll be in a position to provide just a status update and perhaps a data update from that study prior to the J.P. Morgan meeting in January. So, looking, you know, very much looking forward to that. You know, the dose escalation is going very well there, and we're moving through the dose escalation cohorts in patients with renal cell, gastric, hepatocellular, and endometrial cancers. Our PD-1, PD-L1 bispecific antibody, we presented data at ASCO in June, and in a dose escalation phase one study, we saw... I think very important responses in the post-PD-1 patient population in patients with triple negative breast cancer, non-small cell lung cancer, and Hodgkin's lymphoma. And based on that, we initiated cohort expansions in the Phase I study in those three indications. The enrollment into the cohort expansions is going very well and will be in a position to report a status update and some new data by the end of the year as well. Ideally, some report on some additional efficacy signals that we're seeing. And then finally, our 471 drug, our CD137 agonist antibody. I think we made a very important biomarker discovery there, which is N-CAM expression on tumors. So now we've initiated an N-CAM positive phase two study, which is going to enroll patients with mostly neuroendocrine tumors. And, you know, it's interesting, you know, some others have now made this observation that neuroendocrine tumors are sort of uniquely. Amenable to CD137 targeting. So we're about to, so we've initiated a phase two study in patients with neuroendocrine tumors, and that's a later 27 data event. You know, but that's another study we're, you know, we're very excited about.
Michael Schmidt, Analyst — Guggenheim
Just on that one, so are these patients selected based on NCAM expression? Yes. Yes. Okay. Maybe just to follow up on, I'm sorry, 10-726, the PD-1-VECHF antibody, the data that you're, the dose escalation study that you're conducting, will that give us some insights into potential differentiation from Ivanacimab, or would you expect a similar profile to emerge there?
Thomas J. Schuetz, CEO
That's an interesting question. We believe that drug is, well, we believe, of course, that that drug is better. It's better pre-clinically. It's better in vitro. Now, let's be serious here for a minute. Ivanesimab has done thousands of patients of randomized trials, so the only way we'll ever be able to say we're better is with clinical data. So, I expect us to be able to show differentiated activity. You know, I think. Ideally, frankly, I would love to see monotherapy activity in the post-checkpoint patient population. That would be ideal. I think the Ivanesimab data are all non-small cell lung. BTC, etc., are all, you know, combination, you know, with chemotherapy or checkpoints or ADCs, so, you know, I think, and there are, among the indications we're studying, you know, I think there are indications where, you know, a monotherapy signal would be very, very meaningful. So, renal cell, for example, right? Post-Cabo Nevo, you know, post-salvage VEGF TKI. You know, there's a population where, you know, we could potentially, you know, go straight into an approval study, conceivably.
Michael Schmidt, Analyst — Guggenheim
Right.
Thomas J. Schuetz, CEO
And I think hepatocellular also, you know, frontline, you know, bevetizo, you know, I think, you know, post-frontline bevetizo, you know, would be a place that would be, you know, sort of very straightforward for us to go.
Michael Schmidt, Analyst — Guggenheim
Okay, and then just a quick one in the last 22 seconds on 8371, the status update by the end of this year, I guess, how many patients will be included in that?
Thomas J. Schuetz, CEO
I'm sorry, it's probably going to be in the 20s, I would say, something like that. I don't know the exact number today.
Michael Schmidt, Analyst — Guggenheim
Up from 12, I think it was before? 15. Okay, great. So, looking forward to that. Our time is up, right on the dots. Appreciate it, Tom. Great. Thanks, Michael.